ImmunoCellular Therapeutics (IMUC) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts IMUC Hot Sheet
Join SI Premium – FREE
ImmunoCellular Therapeutics (NYSE: IMUC) reported Q3 EPS of ($0.04), in-line with the analyst estimate of ($0.04).
For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Citigroup (C) Tops Q2 EPS by 42c
- KeyBanc cuts Apple to Underweight, cites slowing hardware demand
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
